Home

Pfizer (PFE)

24.03
-0.40 (-1.66%)
NYSE · Last Trade: Nov 10th, 1:00 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Pfizer CEO Reportedly Drops F-Bomb On Live TV Discussing Seagen, Metsera Dealsstocktwits.com
Via Stocktwits · November 10, 2025
Markets Breathe Sigh of Relief as Historic Government Shutdown Nears Resolution
Washington D.C. – November 10, 2025 – The United States stock market is experiencing a significant uplift today, as news of an impending resolution to the nation's longest-ever government shutdown sends a wave of positive sentiment across financial markets. After weeks of political deadlock, a bipartisan agreement in the Senate has
Via MarketMinute · November 10, 2025
Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trialbenzinga.com
Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIST trial.
Via Benzinga · November 10, 2025
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billioninvestors.com
The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.
Via Investor's Business Daily · November 10, 2025
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionmonday-com
Via Benzinga · November 10, 2025
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 10, 2025
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faithstocktwits.com
Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.
Via Stocktwits · November 9, 2025
Market Reels from Volatility and Mixed Signals: A Deep Dive into Investor Unease
The past week, from November 1st to November 8th, 2025, has witnessed a significant shift in global market sentiment, moving decisively towards a "risk-off" stance. Investors are grappling with heightened volatility and a pervasive sense of unease, as U.S. and international equity markets have experienced broad declines, snapping recent
Via MarketMinute · November 8, 2025
2 No-Brainer Dividend Stocks to Buy With $100 in Novemberfool.com
There's no need to break the bank to get your hands on excellent dividend payers.
Via The Motley Fool · November 8, 2025
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.fool.com
Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.
Via The Motley Fool · November 8, 2025
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominancebenzinga.com
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
Via Benzinga · November 8, 2025
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcybenzinga.com
Via Benzinga · November 7, 2025
Why Novo Nordisk Stock Is Sinking This Weekfool.com
The global drugmaker is facing some headwinds related to tough competition.
Via The Motley Fool · November 7, 2025
The Stock Market Is Signaling a Recession. Here's How to Prepare Your Portfolio.
The financial markets are increasingly flashing warning signs that an economic recession may be on the horizon, prompting investors to re-evaluate their strategies. A confluence of indicators, from inverted yield curves to softening corporate earnings and shifting consumer sentiment, suggests that the robust growth seen in recent years could be
Via MarketMinute · November 7, 2025
Friday's session: most active stock in the S&P500 indexchartmill.com
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements.
Via Chartmill · November 7, 2025
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.investors.com
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.
Via Investor's Business Daily · November 7, 2025
Tech Sell-Off Rocks Wall Street: Nasdaq, S&P 500, and Dow Sink Amidst Brutal Week for Stocks
New York, NY – November 7, 2025 – The U.S. stock market has been gripped by a significant downturn in early November 2025, culminating in a brutal week that saw the Nasdaq Composite, S&P 500, and Dow Jones Industrial Average all close sharply lower. This market correction is primarily fueled
Via MarketMinute · November 7, 2025
Sangamo (SGMO) Q3 2025 Earnings Call Transcriptfool.com
Sangamo (SGMO) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 6, 2025
Famed Investor Michael Burry Bets Against Nvidia and Palantir to the Tune of $1.1 billion. Is He Right?fool.com
Burry is famous for shorting the market during the mortgage crisis. Is he going to win big again?
Via The Motley Fool · November 6, 2025
US Stocks Tumble Amid AI Valuation Fears and Mounting Job Worries
The U.S. stock market experienced a notable downturn today, November 6, 2025, as investors grappled with growing apprehension over the lofty valuations of artificial intelligence (AI) stocks and a significantly deteriorating job market. Major indices, including the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average, registered sharp
Via MarketMinute · November 6, 2025
3 Value Stocks That Fall Short
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Via StockStory · November 6, 2025
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as the linchpin in the quest to develop cures for a myriad of debilitating diseases. This significant investment is poised to revolutionize how scientists approach genetic disorders, moving beyond [...]
Via TokenRing AI · November 6, 2025
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRxbenzinga.com
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.
Via Benzinga · November 6, 2025
Stay informed about the most active stocks in the S&P500 index on Thursday's session.chartmill.com
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · November 6, 2025
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Dealbenzinga.com
Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer.
Via Benzinga · November 6, 2025